Metadata record for the manuscript: Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY2 breast cancer trial

<b>Summary</b>This metadata record provides details of the data supporting the claims of the related manuscript: "Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY2 breast cancer trial".<br>The related study aimed to determine whether the AKT signaling axis proteins/genes specifically predicted response to AKT inhibitor MK2206 (M). To this end, 26 phospho-proteins and 10 genes involved in AKTmTOR-HER signaling were tested.<br>The data are gene expression and reverse phase protein array (RPPA) data from 150 women with high-risk stage II and III early breast cancer who were enrolled in the multicenter, multi-arm, neo-adjuvant I-SPY 2 TRIAL (NCT01042379; IND105139).<br><b>Data access</b>De-identified molecular and clinical data have been deposited in NCBI's <i>Gene </i><i>Expression Omnibus</i>. The superseries accession number is GSE150576. The constituent series accession number for the gene expression data is GSE149322, and the constituent series accession number for the RPPA protein/phospho-protein data is GSE150575. In addition, linear transformation parameters (gene expression) and normalisation parameters (mean, sd per RPPA endpoint) to transform raw to normalised data are available as supplemental files on <i>Gene Expression Omnibus</i>, along with the normalised data matrix used in the analysis (gene expression file: GSE149322_ExpDat_ISPY2_MK2206_n150.txt.gz).<br><br><br><b>Name of Institutional Review Board or ethics committee that approved the study</b>The protocol used in the study was approved by Institutional Review Boards at all participating institutions: University of California, San Francisco; George Mason University; Quantum Leap Healthcare Collaborative; University of Texas, MD Anderson Cancer Center; Berry Consultants, LLC. <br>